244 related articles for article (PubMed ID: 36945256)
1. Disulfide Bond-Based SN38 Prodrug Nanoassemblies with High Drug Loading and Reduction-Triggered Drug Release for Pancreatic Cancer Therapy.
Zhong ZX; Li XZ; Liu JT; Qin N; Duan HQ; Duan XC
Int J Nanomedicine; 2023; 18():1281-1298. PubMed ID: 36945256
[TBL] [Abstract][Full Text] [Related]
2. Novel disulfide bond bridged 7-ethyl-10-hydroxyl camptothecin-undecanoic acid conjugate/human serum albumin nanoparticles for breast cancer therapy.
Zhang Y; Wang J; Liu C; Xing H; Jiang Y; Li X
J Mater Chem B; 2023 Mar; 11(11):2478-2489. PubMed ID: 36843543
[TBL] [Abstract][Full Text] [Related]
3. Methotrexate-based amphiphilic prodrug nanoaggregates for co-administration of multiple therapeutics and synergistic cancer therapy.
Hou M; Gao YE; Shi X; Bai S; Ma X; Li B; Xiao B; Xue P; Kang Y; Xu Z
Acta Biomater; 2018 Sep; 77():228-239. PubMed ID: 30006314
[TBL] [Abstract][Full Text] [Related]
4. Efficient Click Synthesis of a Protonized and Reduction-Sensitive Amphiphilic Small-Molecule Prodrug Containing Camptothecin and Gemcitabine for a Drug Self-Delivery System.
Dong S; He J; Sun Y; Li D; Li L; Zhang M; Ni P
Mol Pharm; 2019 Sep; 16(9):3770-3779. PubMed ID: 31348660
[TBL] [Abstract][Full Text] [Related]
5. In vivo tailor-made protein corona of a prodrug-based nanoassembly fabricated by redox dual-sensitive paclitaxel prodrug for the superselective treatment of breast cancer.
Zhang D; Yang J; Guan J; Yang B; Zhang S; Sun M; Yang R; Zhang T; Zhang R; Kan Q; Zhang H; He Z; Shang L; Sun J
Biomater Sci; 2018 Aug; 6(9):2360-2374. PubMed ID: 30019051
[TBL] [Abstract][Full Text] [Related]
6. Precise engineering of disulfide bond-bridged prodrug nanoassemblies to balance antitumor efficacy and safety.
Sun Y; Wang S; Li Y; Wang D; Zhang Y; Zhang H; Lei H; Liu X; Sun J; Sun B; He Z
Acta Biomater; 2023 Feb; 157():417-427. PubMed ID: 36513247
[TBL] [Abstract][Full Text] [Related]
7. Integrating a novel SN38 prodrug into the PEGylated liposomal system as a robust platform for efficient cancer therapy in solid tumors.
Fang T; Dong Y; Zhang X; Xie K; Lin L; Wang H
Int J Pharm; 2016 Oct; 512(1):39-48. PubMed ID: 27544846
[TBL] [Abstract][Full Text] [Related]
8. Disulfide Bond-Driven Oxidation- and Reduction-Responsive Prodrug Nanoassemblies for Cancer Therapy.
Sun B; Luo C; Yu H; Zhang X; Chen Q; Yang W; Wang M; Kan Q; Zhang H; Wang Y; He Z; Sun J
Nano Lett; 2018 Jun; 18(6):3643-3650. PubMed ID: 29726685
[TBL] [Abstract][Full Text] [Related]
9. Hydrophobized SN38 to redox-hypersensitive nanorods for cancer therapy.
Zheng Y; Yan X; Wang Y; Duan X; Wang X; Chen C; Tian D; Luo Z; Zhang Z; Zeng Y
J Mater Chem B; 2019 Jan; 7(2):265-276. PubMed ID: 32254551
[TBL] [Abstract][Full Text] [Related]
10. Preparation of a camptothecin prodrug with glutathione-responsive disulfide linker for anticancer drug delivery.
Xu Z; Wang D; Xu S; Liu X; Zhang X; Zhang H
Chem Asian J; 2014 Jan; 9(1):199-205. PubMed ID: 24136878
[TBL] [Abstract][Full Text] [Related]
11. Trisulfide bond-mediated doxorubicin dimeric prodrug nanoassemblies with high drug loading, high self-assembly stability, and high tumor selectivity.
Yang Y; Sun B; Zuo S; Li X; Zhou S; Li L; Luo C; Liu H; Cheng M; Wang Y; Wang S; He Z; Sun J
Sci Adv; 2020 Nov; 6(45):. PubMed ID: 33148644
[TBL] [Abstract][Full Text] [Related]
12. Carrier-free nanoparticles of camptothecin prodrug for chemo-photothermal therapy: the making, in vitro and in vivo testing.
Ao M; Yu F; Li Y; Zhong M; Tang Y; Yang H; Wu X; Zhuang Y; Wang H; Sun X; Hong X; Chen XD
J Nanobiotechnology; 2021 Oct; 19(1):350. PubMed ID: 34717646
[TBL] [Abstract][Full Text] [Related]
13. A nanotherapeutic strategy to overcome chemoresistance to irinotecan/7-ethyl-10-hydroxy-camptothecin in colorectal cancer.
Huang Q; Liu X; Wang H; Liu X; Zhang Q; Li K; Chen Y; Zhu Q; Shen Y; Sui M
Acta Biomater; 2022 Jan; 137():262-275. PubMed ID: 34718178
[TBL] [Abstract][Full Text] [Related]
14. A novel carbon-nanodots-based theranostic nano-drug delivery system for mitochondria-targeted imaging and glutathione-activated delivering camptothecin.
Gong X; Wang Z; Zhang L; Dong W; Wang R; Liu Y; Song S; Hu Q; Du F; Shuang S; Dong C
Colloids Surf B Biointerfaces; 2022 Oct; 218():112712. PubMed ID: 35921692
[TBL] [Abstract][Full Text] [Related]
15. Probing the impact of sulfur/selenium/carbon linkages on prodrug nanoassemblies for cancer therapy.
Sun B; Luo C; Zhang X; Guo M; Sun M; Yu H; Chen Q; Yang W; Wang M; Zuo S; Chen P; Kan Q; Zhang H; Wang Y; He Z; Sun J
Nat Commun; 2019 Jul; 10(1):3211. PubMed ID: 31324811
[TBL] [Abstract][Full Text] [Related]
16. Dual 7-ethyl-10-hydroxycamptothecin conjugated phospholipid prodrug assembled liposomes with in vitro anticancer effects.
Du Y; Zhang W; He R; Ismail M; Ling L; Yao C; Fu Z; Li X
Bioorg Med Chem; 2017 Jun; 25(12):3247-3258. PubMed ID: 28465086
[TBL] [Abstract][Full Text] [Related]
17. Novel lipophilic SN38 prodrug forming stable liposomes for colorectal carcinoma therapy.
Xing J; Zhang X; Wang Z; Zhang H; Chen P; Zhou G; Sun C; Gu N; Ji M
Int J Nanomedicine; 2019; 14():5201-5213. PubMed ID: 31371956
[No Abstract] [Full Text] [Related]
18. Drug Release from Disulfide-Linked Prodrugs: Role of Thiol Agents.
Lei J; Zhang Q; Jin X; Lu H; Wang S; Li T; Sheng Y; Zhang F; Zheng Y
Mol Pharm; 2021 Jul; 18(7):2777-2785. PubMed ID: 34121410
[TBL] [Abstract][Full Text] [Related]
19. Comparison of two self-assembled macromolecular prodrug micelles with different conjugate positions of SN38 for enhancing antitumor activity.
Liu Y; Piao H; Gao Y; Xu C; Tian Y; Wang L; Liu J; Tang B; Zou M; Cheng G
Int J Nanomedicine; 2015; 10():2295-311. PubMed ID: 25848251
[TBL] [Abstract][Full Text] [Related]
20. A ROS-response hyaluronic acid-coated/chitosan polymer prodrug for enhanced tumour targeting efficacy of SN38.
Qin J; Sun M; Zhen Y; Li J; Wang D
J Drug Target; 2023 Jul; 31(6):623-633. PubMed ID: 37216422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
